Green Cross MS rises 11.54% amid upward trend in COVID-19 (diagnostics/treatment/vaccine development) theme

On the 22nd, the COVID-19 (diagnosis/treatment/vaccine development, etc.) theme rose by 3.07% compared to the previous day, showing strength, while Green Cross MS, a related stock attracting attention, surged by 11.54% compared to the previous day. Green Cross MS is known as a manufacturer and seller of in vitro diagnostic reagents and diagnostic reagents.

[Graph] Major stock price changes in the COVID-19 (diagnosis/treatment/vaccine development, etc.) theme



According to the analysis by Thinkpool Robo Algorithm RASSI, Green Cross MS’s quant financial score is 6.45 points, which is lower in stability, profitability, and growth scores compared to the average of other stocks related to COVID-19 (diagnosis/treatment/vaccine development, etc.). This can be interpreted as Green Cross MS having relatively low investment attractiveness compared to other stocks from a financial perspective. On the other hand, United Pharmaceutical ranked first in quant financial ranking with higher growth, stability, and profitability scores compared to the average of other stocks.

[Table] Top stocks by financial score within the theme


※ The quant financial score is the result of the Robo Algorithm’s analysis based on each company’s sales growth rate, equity growth rate, debt ratio, current ratio, ROA, ROE, etc.

※ This article was generated in real-time by an article automatic generation algorithm jointly developed by Asia Economy and the financial AI specialist company Thinkpool.

This content was produced with the assistance of AI translation services.